nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Mental retardation—Capecitabine—esophageal cancer	0.043	0.043	CcSEcCtD
Degarelix—Nodule—Methotrexate—esophageal cancer	0.0238	0.0238	CcSEcCtD
Degarelix—Febrile neutropenia—Cisplatin—esophageal cancer	0.0211	0.0211	CcSEcCtD
Degarelix—Joint swelling—Capecitabine—esophageal cancer	0.0191	0.0191	CcSEcCtD
Degarelix—Night sweats—Capecitabine—esophageal cancer	0.0174	0.0174	CcSEcCtD
Degarelix—Abscess—Cisplatin—esophageal cancer	0.0161	0.0161	CcSEcCtD
Degarelix—Febrile neutropenia—Capecitabine—esophageal cancer	0.0156	0.0156	CcSEcCtD
Degarelix—Pain—Carboplatin—esophageal cancer	0.0132	0.0132	CcSEcCtD
Degarelix—Osteoporosis—Methotrexate—esophageal cancer	0.0125	0.0125	CcSEcCtD
Degarelix—Body temperature increased—Carboplatin—esophageal cancer	0.0122	0.0122	CcSEcCtD
Degarelix—Febrile neutropenia—Methotrexate—esophageal cancer	0.0116	0.0116	CcSEcCtD
Degarelix—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.0105	0.0105	CcSEcCtD
Degarelix—Nocturia—Capecitabine—esophageal cancer	0.0101	0.0101	CcSEcCtD
Degarelix—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00992	0.00992	CcSEcCtD
Degarelix—Inflammation—Capecitabine—esophageal cancer	0.00967	0.00967	CcSEcCtD
Degarelix—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00938	0.00938	CcSEcCtD
Degarelix—Injection site reaction—Capecitabine—esophageal cancer	0.00932	0.00932	CcSEcCtD
Degarelix—Influenza like illness—Capecitabine—esophageal cancer	0.00911	0.00911	CcSEcCtD
Degarelix—Abscess—Methotrexate—esophageal cancer	0.00882	0.00882	CcSEcCtD
Degarelix—Breast disorder—Cisplatin—esophageal cancer	0.00835	0.00835	CcSEcCtD
Degarelix—Mental disability—Capecitabine—esophageal cancer	0.00814	0.00814	CcSEcCtD
Degarelix—Diabetes mellitus—Capecitabine—esophageal cancer	0.00783	0.00783	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00783	0.00783	CcSEcCtD
Degarelix—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00778	0.00778	CcSEcCtD
Degarelix—Bone disorder—Methotrexate—esophageal cancer	0.00773	0.00773	CcSEcCtD
Degarelix—Swelling—Capecitabine—esophageal cancer	0.00772	0.00772	CcSEcCtD
Degarelix—Abdominal discomfort—Cisplatin—esophageal cancer	0.00765	0.00765	CcSEcCtD
Degarelix—Libido decreased—Capecitabine—esophageal cancer	0.00734	0.00734	CcSEcCtD
Degarelix—Hot flush—Capecitabine—esophageal cancer	0.00728	0.00728	CcSEcCtD
Degarelix—Menopausal symptoms—Capecitabine—esophageal cancer	0.00721	0.00721	CcSEcCtD
Degarelix—Inflammation—Methotrexate—esophageal cancer	0.0072	0.0072	CcSEcCtD
Degarelix—Atrial fibrillation—Capecitabine—esophageal cancer	0.00718	0.00718	CcSEcCtD
Degarelix—Renal impairment—Capecitabine—esophageal cancer	0.00715	0.00715	CcSEcCtD
Degarelix—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00702	0.00702	CcSEcCtD
Degarelix—Renal failure—Cisplatin—esophageal cancer	0.007	0.007	CcSEcCtD
Degarelix—Myocardial infarction—Cisplatin—esophageal cancer	0.00698	0.00698	CcSEcCtD
Degarelix—Cardiac failure—Capecitabine—esophageal cancer	0.00698	0.00698	CcSEcCtD
Degarelix—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00675	0.00675	CcSEcCtD
Degarelix—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00673	0.00673	CcSEcCtD
Degarelix—Urinary tract disorder—Cisplatin—esophageal cancer	0.00631	0.00631	CcSEcCtD
Degarelix—Urethral disorder—Cisplatin—esophageal cancer	0.00626	0.00626	CcSEcCtD
Degarelix—Gynaecomastia—Methotrexate—esophageal cancer	0.00625	0.00625	CcSEcCtD
Degarelix—Breast disorder—Capecitabine—esophageal cancer	0.00615	0.00615	CcSEcCtD
Degarelix—Muscular weakness—Capecitabine—esophageal cancer	0.006	0.006	CcSEcCtD
Degarelix—Eye disorder—Cisplatin—esophageal cancer	0.00597	0.00597	CcSEcCtD
Degarelix—Cardiac disorder—Cisplatin—esophageal cancer	0.00593	0.00593	CcSEcCtD
Degarelix—Diabetes mellitus—Methotrexate—esophageal cancer	0.00583	0.00583	CcSEcCtD
Degarelix—Immune system disorder—Cisplatin—esophageal cancer	0.00577	0.00577	CcSEcCtD
Degarelix—Mediastinal disorder—Cisplatin—esophageal cancer	0.00576	0.00576	CcSEcCtD
Degarelix—Arrhythmia—Cisplatin—esophageal cancer	0.00571	0.00571	CcSEcCtD
Degarelix—Alopecia—Cisplatin—esophageal cancer	0.00565	0.00565	CcSEcCtD
Degarelix—Abdominal discomfort—Capecitabine—esophageal cancer	0.00564	0.00564	CcSEcCtD
Degarelix—Erythema—Cisplatin—esophageal cancer	0.00556	0.00556	CcSEcCtD
Degarelix—Malnutrition—Cisplatin—esophageal cancer	0.00556	0.00556	CcSEcCtD
Degarelix—Dysuria—Capecitabine—esophageal cancer	0.0055	0.0055	CcSEcCtD
Degarelix—Weight increased—Capecitabine—esophageal cancer	0.00535	0.00535	CcSEcCtD
Degarelix—Muscle spasms—Cisplatin—esophageal cancer	0.00535	0.00535	CcSEcCtD
Degarelix—Weight decreased—Capecitabine—esophageal cancer	0.00532	0.00532	CcSEcCtD
Degarelix—Hyperglycaemia—Capecitabine—esophageal cancer	0.00531	0.00531	CcSEcCtD
Degarelix—Vision blurred—Cisplatin—esophageal cancer	0.00524	0.00524	CcSEcCtD
Degarelix—Depression—Capecitabine—esophageal cancer	0.00523	0.00523	CcSEcCtD
Degarelix—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00517	0.00517	CcSEcCtD
Degarelix—Ill-defined disorder—Cisplatin—esophageal cancer	0.00516	0.00516	CcSEcCtD
Degarelix—Renal failure—Capecitabine—esophageal cancer	0.00516	0.00516	CcSEcCtD
Degarelix—Myocardial infarction—Capecitabine—esophageal cancer	0.00514	0.00514	CcSEcCtD
Degarelix—Anaemia—Cisplatin—esophageal cancer	0.00514	0.00514	CcSEcCtD
Degarelix—Urinary tract infection—Capecitabine—esophageal cancer	0.0051	0.0051	CcSEcCtD
Degarelix—Malaise—Cisplatin—esophageal cancer	0.00502	0.00502	CcSEcCtD
Degarelix—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00496	0.00496	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0047	0.0047	CcSEcCtD
Degarelix—Hypoaesthesia—Capecitabine—esophageal cancer	0.00469	0.00469	CcSEcCtD
Degarelix—Discomfort—Cisplatin—esophageal cancer	0.00468	0.00468	CcSEcCtD
Degarelix—Urinary tract disorder—Capecitabine—esophageal cancer	0.00465	0.00465	CcSEcCtD
Degarelix—Oedema peripheral—Capecitabine—esophageal cancer	0.00464	0.00464	CcSEcCtD
Degarelix—Urethral disorder—Capecitabine—esophageal cancer	0.00462	0.00462	CcSEcCtD
Degarelix—Breast disorder—Methotrexate—esophageal cancer	0.00458	0.00458	CcSEcCtD
Degarelix—Anaphylactic shock—Cisplatin—esophageal cancer	0.00454	0.00454	CcSEcCtD
Degarelix—Nervous system disorder—Cisplatin—esophageal cancer	0.00445	0.00445	CcSEcCtD
Degarelix—Skin disorder—Cisplatin—esophageal cancer	0.00441	0.00441	CcSEcCtD
Degarelix—Eye disorder—Capecitabine—esophageal cancer	0.0044	0.0044	CcSEcCtD
Degarelix—Hyperhidrosis—Cisplatin—esophageal cancer	0.00439	0.00439	CcSEcCtD
Degarelix—Cardiac disorder—Capecitabine—esophageal cancer	0.00437	0.00437	CcSEcCtD
Degarelix—Angiopathy—Capecitabine—esophageal cancer	0.00427	0.00427	CcSEcCtD
Degarelix—Immune system disorder—Capecitabine—esophageal cancer	0.00425	0.00425	CcSEcCtD
Degarelix—Mediastinal disorder—Capecitabine—esophageal cancer	0.00424	0.00424	CcSEcCtD
Degarelix—Hypotension—Cisplatin—esophageal cancer	0.00424	0.00424	CcSEcCtD
Degarelix—Chills—Capecitabine—esophageal cancer	0.00423	0.00423	CcSEcCtD
Degarelix—Arrhythmia—Capecitabine—esophageal cancer	0.00421	0.00421	CcSEcCtD
Degarelix—Abdominal discomfort—Methotrexate—esophageal cancer	0.0042	0.0042	CcSEcCtD
Degarelix—Alopecia—Capecitabine—esophageal cancer	0.00416	0.00416	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00414	0.00414	CcSEcCtD
Degarelix—Mental disorder—Capecitabine—esophageal cancer	0.00413	0.00413	CcSEcCtD
Degarelix—Malnutrition—Capecitabine—esophageal cancer	0.0041	0.0041	CcSEcCtD
Degarelix—Erythema—Capecitabine—esophageal cancer	0.0041	0.0041	CcSEcCtD
Degarelix—Dysuria—Methotrexate—esophageal cancer	0.0041	0.0041	CcSEcCtD
Degarelix—Dyspnoea—Cisplatin—esophageal cancer	0.00405	0.00405	CcSEcCtD
Degarelix—Erectile dysfunction—Methotrexate—esophageal cancer	0.00403	0.00403	CcSEcCtD
Degarelix—Back pain—Capecitabine—esophageal cancer	0.00397	0.00397	CcSEcCtD
Degarelix—Decreased appetite—Cisplatin—esophageal cancer	0.00395	0.00395	CcSEcCtD
Degarelix—Muscle spasms—Capecitabine—esophageal cancer	0.00394	0.00394	CcSEcCtD
Degarelix—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00392	0.00392	CcSEcCtD
Degarelix—Depression—Methotrexate—esophageal cancer	0.00389	0.00389	CcSEcCtD
Degarelix—Pain—Cisplatin—esophageal cancer	0.00388	0.00388	CcSEcCtD
Degarelix—Vision blurred—Capecitabine—esophageal cancer	0.00386	0.00386	CcSEcCtD
Degarelix—Renal failure—Methotrexate—esophageal cancer	0.00384	0.00384	CcSEcCtD
Degarelix—Ill-defined disorder—Capecitabine—esophageal cancer	0.0038	0.0038	CcSEcCtD
Degarelix—Anaemia—Capecitabine—esophageal cancer	0.00379	0.00379	CcSEcCtD
Degarelix—Feeling abnormal—Cisplatin—esophageal cancer	0.00374	0.00374	CcSEcCtD
Degarelix—Malaise—Capecitabine—esophageal cancer	0.0037	0.0037	CcSEcCtD
Degarelix—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00369	0.00369	CcSEcCtD
Degarelix—Palpitations—Capecitabine—esophageal cancer	0.00362	0.00362	CcSEcCtD
Degarelix—Body temperature increased—Cisplatin—esophageal cancer	0.00359	0.00359	CcSEcCtD
Degarelix—Hypertension—Capecitabine—esophageal cancer	0.00354	0.00354	CcSEcCtD
Degarelix—Arthralgia—Capecitabine—esophageal cancer	0.00349	0.00349	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00347	0.00347	CcSEcCtD
Degarelix—Urinary tract disorder—Methotrexate—esophageal cancer	0.00346	0.00346	CcSEcCtD
Degarelix—Discomfort—Capecitabine—esophageal cancer	0.00345	0.00345	CcSEcCtD
Degarelix—Urethral disorder—Methotrexate—esophageal cancer	0.00344	0.00344	CcSEcCtD
Degarelix—Dry mouth—Capecitabine—esophageal cancer	0.00341	0.00341	CcSEcCtD
Degarelix—Hypersensitivity—Cisplatin—esophageal cancer	0.00334	0.00334	CcSEcCtD
Degarelix—Nervous system disorder—Capecitabine—esophageal cancer	0.00328	0.00328	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—esophageal cancer	0.00328	0.00328	CcSEcCtD
Degarelix—Asthenia—Cisplatin—esophageal cancer	0.00326	0.00326	CcSEcCtD
Degarelix—Cardiac disorder—Methotrexate—esophageal cancer	0.00325	0.00325	CcSEcCtD
Degarelix—Skin disorder—Capecitabine—esophageal cancer	0.00325	0.00325	CcSEcCtD
Degarelix—Hyperhidrosis—Capecitabine—esophageal cancer	0.00323	0.00323	CcSEcCtD
Degarelix—Angiopathy—Methotrexate—esophageal cancer	0.00318	0.00318	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—esophageal cancer	0.00317	0.00317	CcSEcCtD
Degarelix—Mediastinal disorder—Methotrexate—esophageal cancer	0.00316	0.00316	CcSEcCtD
Degarelix—Chills—Methotrexate—esophageal cancer	0.00315	0.00315	CcSEcCtD
Degarelix—Hypotension—Capecitabine—esophageal cancer	0.00313	0.00313	CcSEcCtD
Degarelix—Diarrhoea—Cisplatin—esophageal cancer	0.00311	0.00311	CcSEcCtD
Degarelix—Alopecia—Methotrexate—esophageal cancer	0.0031	0.0031	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—esophageal cancer	0.00307	0.00307	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—esophageal cancer	0.00305	0.00305	CcSEcCtD
Degarelix—Erythema—Methotrexate—esophageal cancer	0.00305	0.00305	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00305	0.00305	CcSEcCtD
Degarelix—Insomnia—Capecitabine—esophageal cancer	0.00303	0.00303	CcSEcCtD
Degarelix—Dyspnoea—Capecitabine—esophageal cancer	0.00298	0.00298	CcSEcCtD
Degarelix—Back pain—Methotrexate—esophageal cancer	0.00295	0.00295	CcSEcCtD
Degarelix—Decreased appetite—Capecitabine—esophageal cancer	0.00291	0.00291	CcSEcCtD
Degarelix—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00289	0.00289	CcSEcCtD
Degarelix—Vomiting—Cisplatin—esophageal cancer	0.00289	0.00289	CcSEcCtD
Degarelix—Fatigue—Capecitabine—esophageal cancer	0.00288	0.00288	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—esophageal cancer	0.00288	0.00288	CcSEcCtD
Degarelix—Rash—Cisplatin—esophageal cancer	0.00286	0.00286	CcSEcCtD
Degarelix—Constipation—Capecitabine—esophageal cancer	0.00286	0.00286	CcSEcCtD
Degarelix—Pain—Capecitabine—esophageal cancer	0.00286	0.00286	CcSEcCtD
Degarelix—Dermatitis—Cisplatin—esophageal cancer	0.00286	0.00286	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—esophageal cancer	0.00283	0.00283	CcSEcCtD
Degarelix—Anaemia—Methotrexate—esophageal cancer	0.00282	0.00282	CcSEcCtD
Degarelix—Feeling abnormal—Capecitabine—esophageal cancer	0.00276	0.00276	CcSEcCtD
Degarelix—Malaise—Methotrexate—esophageal cancer	0.00275	0.00275	CcSEcCtD
Degarelix—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00274	0.00274	CcSEcCtD
Degarelix—Nausea—Cisplatin—esophageal cancer	0.0027	0.0027	CcSEcCtD
Degarelix—Urticaria—Capecitabine—esophageal cancer	0.00266	0.00266	CcSEcCtD
Degarelix—Body temperature increased—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Degarelix—Abdominal pain—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Degarelix—Arthralgia—Methotrexate—esophageal cancer	0.0026	0.0026	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00258	0.00258	CcSEcCtD
Degarelix—Discomfort—Methotrexate—esophageal cancer	0.00257	0.00257	CcSEcCtD
Degarelix—Anaphylactic shock—Methotrexate—esophageal cancer	0.00249	0.00249	CcSEcCtD
Degarelix—Hypersensitivity—Capecitabine—esophageal cancer	0.00247	0.00247	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—esophageal cancer	0.00244	0.00244	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—esophageal cancer	0.00242	0.00242	CcSEcCtD
Degarelix—Hyperhidrosis—Methotrexate—esophageal cancer	0.00241	0.00241	CcSEcCtD
Degarelix—Asthenia—Capecitabine—esophageal cancer	0.0024	0.0024	CcSEcCtD
Degarelix—Pruritus—Capecitabine—esophageal cancer	0.00237	0.00237	CcSEcCtD
Degarelix—Hypotension—Methotrexate—esophageal cancer	0.00233	0.00233	CcSEcCtD
Degarelix—Diarrhoea—Capecitabine—esophageal cancer	0.00229	0.00229	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00227	0.00227	CcSEcCtD
Degarelix—Insomnia—Methotrexate—esophageal cancer	0.00225	0.00225	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—esophageal cancer	0.00222	0.00222	CcSEcCtD
Degarelix—Dizziness—Capecitabine—esophageal cancer	0.00221	0.00221	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—esophageal cancer	0.00217	0.00217	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00215	0.00215	CcSEcCtD
Degarelix—Fatigue—Methotrexate—esophageal cancer	0.00215	0.00215	CcSEcCtD
Degarelix—Pain—Methotrexate—esophageal cancer	0.00213	0.00213	CcSEcCtD
Degarelix—Vomiting—Capecitabine—esophageal cancer	0.00213	0.00213	CcSEcCtD
Degarelix—Rash—Capecitabine—esophageal cancer	0.00211	0.00211	CcSEcCtD
Degarelix—Dermatitis—Capecitabine—esophageal cancer	0.00211	0.00211	CcSEcCtD
Degarelix—Headache—Capecitabine—esophageal cancer	0.0021	0.0021	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—esophageal cancer	0.00205	0.00205	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00204	0.00204	CcSEcCtD
Degarelix—Nausea—Capecitabine—esophageal cancer	0.00199	0.00199	CcSEcCtD
Degarelix—Urticaria—Methotrexate—esophageal cancer	0.00198	0.00198	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Degarelix—Hypersensitivity—Methotrexate—esophageal cancer	0.00184	0.00184	CcSEcCtD
Degarelix—Asthenia—Methotrexate—esophageal cancer	0.00179	0.00179	CcSEcCtD
Degarelix—Pruritus—Methotrexate—esophageal cancer	0.00176	0.00176	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—esophageal cancer	0.0017	0.0017	CcSEcCtD
Degarelix—Dizziness—Methotrexate—esophageal cancer	0.00165	0.00165	CcSEcCtD
Degarelix—Vomiting—Methotrexate—esophageal cancer	0.00158	0.00158	CcSEcCtD
Degarelix—Rash—Methotrexate—esophageal cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Dermatitis—Methotrexate—esophageal cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Headache—Methotrexate—esophageal cancer	0.00156	0.00156	CcSEcCtD
Degarelix—Nausea—Methotrexate—esophageal cancer	0.00148	0.00148	CcSEcCtD
